Recent Regulatory Decisions in Multiple Myeloma and Lung Cancer

This week, we’re discussing recent regulatory decisions, ranging from FDA approvals in multiple myeloma and non–small cell lung cancer to the withdrawal of a widely used drug’s indication for small cell lung cancer.

---